BioAtla, Inc. (BCAB)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
3.91 USD
+0.09
(2.356%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.91 |
Hot Take ↕ | July 11, 2026, 4:39 a.m. EDT
The investment case for BioAtla is effectively extinguished by a perfect storm of existential corporate distress and deteriorating fundamentals. The company is actively shedding 70% of its workforce and weighing asset sales, signaling a desperate attempt to survive rather than grow. Financially, the balance sheet is crumbling with a current ratio of 0.15, massive negative free cash flow, and a book value that is deeply negative. The stock has suffered a catastrophic 99% decline over the last four years, with every single year showing negative returns, confirming a structural implosion of value rather than a temporary setback. While the recent price action shows a slight bounce off the lows, this is likely a liquidity event driven by the impending Nasdaq suspension and share consolidation, not a genuine recovery. The options market reflects this grim reality, with traders buying deep out-of-the-money puts to bet on further carnage. There is no credible path to profitability or a return to health visible in the data; this is a distressed asset with no margin of safety. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.116667 |
| MSTL | 0.181157 |
| AutoETS | 0.200423 |
| AutoARIMA | 0.200433 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 19.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.034 |
| Excess Kurtosis | 0.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.586 |
| Market Cap | 6,488,856 |
| Forward P/E | -2.93 |
| Beta | 0.75 |
| Website | https://www.bioatla.com |
As of July 11, 2026, 4:39 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest is significantly higher than call open interest, with heavy concentration in strikes well below the current price (0.5 and 1.5). This indicates a 'bear put spread' or hedging strategy where investors are betting on further declines or protecting existing long positions against a collapse, rather than anticipating a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8085213 |
| Address1 | 11,085 Torreyana Road |
| All Time High | 3,831.5 |
| All Time Low | 3.12 |
| Ask | 4.92 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 64,030 |
| Average Daily Volume3 Month | 51,000 |
| Average Volume | 51,000 |
| Average Volume10Days | 64,030 |
| Beta | 0.75 |
| Bid | 2.96 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | -22.481 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.91 |
| Current Ratio | 0.149 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.2 |
| Day Low | 3.8001 |
| Display Name | BioAtla |
| Earnings Call Timestamp End | 1,763,069,400 |
| Earnings Call Timestamp Start | 1,763,069,400 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -49,589,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.214 |
| Enterprise To Revenue | 5.306 |
| Enterprise Value | 10,611,581 |
| Eps Forward | -1.33667 |
| Eps Trailing Twelve Months | -41.56 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 558 0709 |
| Fifty Day Average | 3.9069 |
| Fifty Day Average Change | 0.0031001568 |
| Fifty Day Average Change Percent | 0.00079350814 |
| Fifty Two Week Change Percent | -80.85213 |
| Fifty Two Week High | 71.5 |
| Fifty Two Week High Change | -67.59 |
| Fifty Two Week High Change Percent | -0.94531465 |
| Fifty Two Week Low | 3.12 |
| Fifty Two Week Low Change | 0.7900002 |
| Fifty Two Week Low Change Percent | 0.2532052 |
| Fifty Two Week Range | 3.12 - 71.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,129,000,000 |
| Float Shares | 1,368,455 |
| Forward Eps | -1.33667 |
| Forward P E | -2.9251797 |
| Free Cashflow | -18,408,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -32,900,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.054580003 |
| Held Percent Institutions | 0.22502 |
| Implied Shares Outstanding | 1,659,554 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-12-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,775,433,600 |
| Last Split Factor | 1:50 |
| Long Business Summary | BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California. |
| Long Name | BioAtla, Inc. |
| Market | us_market |
| Market Cap | 6,488,856 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_105291463 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -50,617,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,339,496 |
| Open | 3.96 |
| Operating Cashflow | -37,183,000 |
| Operating Margins | -24.9495 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 558 0708 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.91 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 3.82 |
| Price Hint | 4 |
| Price To Book | -0.17392464 |
| Price To Sales Trailing12 Months | 3.244428 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.095 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0900002 |
| Regular Market Change Percent | 2.35602 |
| Regular Market Day High | 4.2 |
| Regular Market Day Low | 3.8001 |
| Regular Market Day Range | 3.8001 - 4.2 |
| Regular Market Open | 3.96 |
| Regular Market Previous Close | 3.82 |
| Regular Market Price | 3.91 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 64,781 |
| Return On Assets | -1.33118 |
| Revenue Per Share | 1.586 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 1,659,554 |
| Shares Percent Shares Out | 0.0915 |
| Shares Short | 151,847 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 147,632 |
| Short Name | BioAtla, Inc. |
| Short Percent Of Float | 0.0946 |
| Short Ratio | 2.23 |
| Source Interval | 15 |
| State | CA |
| Symbol | BCAB |
| Total Cash | 1,961,000 |
| Total Cash Per Share | 1.184 |
| Total Debt | 6,094,000 |
| Total Revenue | 2,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -41.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.53535 |
| Two Hundred Day Average Change | -14.625351 |
| Two Hundred Day Average Change Percent | -0.7890518 |
| Type Disp | Equity |
| Volume | 64,781 |
| Website | https://www.bioatla.com |
| Zip | 92,121 |